INOVIO’s COVID-19 vaccine candidate provided broad cross-reactive immune responses In humans against variants
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
On Apr. 15, 2021, CytoDyn announced it had executed an exclusive supply and distribution agreement with Chiral Pharma…
On Apr. 14, 2021, following concern raised around thrombotic events, AstraZeneca offered its reassurance on the safety of…
On Apr. 14, 2021, researchers running the Com-Cov study, launched in February to investigate alternating doses of the…
On Apr. 14, 2021, Moderna announced that results from a preclinical study of the Company’s COVID-19 variant-specific vaccine…
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
On Apr. 13, 2021, a clinical trial testing the safety and efficacy of an investigational monoclonal antibody for…
On Apr. 13, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
On Apr. 13, 2021, Moderna announced that new results from a preclinical study of the Company’s COVID-19 variant-specific…
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
On Apr. 12, 2021, Roche confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability…
On Apr. 12, 2021, Oxford University reported that early treatment with inhaled budesonide shortened recovery time by a…
On Apr. 12, 2021, Thermo Fisher Scientific announced that the U.S. Food and Drug Administration (FDA) had granted…
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 treatment guidelines strongly…
On Apr. 9, 2021, Pfizer announced they had requested amendments to the U.S. Emergency Use Authorization (EUA) of…
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
On Apr. 8, 2021, ImmunityBio reported initial data indicating that a single subcutaneous injection of the companyï¾’s COVID-19…
On Apr. 7, 2021, the National Institutes of Health (NIH) announced that a clinical trial was underway to…
On Apr. 7, 2021, the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) announed…
On Apr. 7, 2021, AIM ImmunoTech announced that it had completed dosing of Cohort 1 in a Phase…
On Apr. 7, 2021, Moderna announced publication of antibody persistence data out to 6 months following the second…
On Apr. 7, 2021, the Centers for Disease Control and Prevention (CDC) announced it had awarded $3 billion…
On Apr. 6, 2021, Moderna and Catalent announced the expansion of their strategic collaboration to dedicate a new…
On Apr. 6, 2021, the Centers for Disease Control and Prevention (CDC) reported that nearly 80 percent of…
On Apr. 5, 2021, the FDA issued an Emergency Use Authorization (EUA) to Symbiotica for the COVID-19 Self-Collected…
On Apr. 5, 2021, Anixa Biosciences announced that based on Proof of Concept animal study results, it was…
On Apr. 5, 2021, Dynavax Technologies announced that Valneva had reported positive initial results for Part A of…
On Apr. 5, 2021, Innovation Pharmaceuticals announced that an independent Data Monitoring Committee (DMC) completed its scheduled review…
On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373,…
On Apr. 4, 2021, Emergent BioSolutions announced it had received a contract modification to increase the original task…